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Abstract 
 
In this review we discuss the effects of exposure to complex PAH mixtures in vitro and in vivo on 
mechanisms related to carcinogenesis. Of particular concern regarding exposure to complex PAH 
mixtures is how interactions between different constituents can affect the carcinogenic response and 
how these might be included in risk assessment. Overall the findings suggest that the responses 
resulting from exposure to complex PAH mixtures is varied and complicated. More- and less-than 
additive effects on bioactivation and DNA damage formation have been observed depending on the 
mixtures studied, and equally dependent on the different test systems that are used. Furthermore, the 
findings show that the commonly used biological end-point of DNA damage formation is 
insufficient for studying mixture effects. At present the assessment of the risk of exposure to 
complex PAH mixtures involves comparison to individual compounds using either a surrogate or a 
component-based potency approach. We discuss how future risk assessment strategies for complex 
PAH mixtures should be based around whole mixture assessment in order to account for interaction 
effects. Inherent to this is the need to incorporate different experimental approaches using robust 
and sensitive biological endpoints. Furthermore, the emphasis on future research should be placed 
on studying real life mixtures that better represent the complex PAH mixtures that humans are 
exposed to. 
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1. Introduction 
 
The field of mixture toxicology and the experimental analysis of chemical mixtures have undergone 
a significant expansion borne out of the need to understand the effects of exposure on human health. 
Historically, experimental approaches have focused on understanding the effects of individual or 
simple combinations of chemicals. However, this approach is being superseded in favor of 
investigating the effects of complex mixtures and understanding of the interactions between 
different chemicals. A review published in the early 1990’s summarized the then status of 
toxicological assessment of complex mixture effects (Mauderly 1993). That the issues pertaining to 
complex mixture assessment presented at that time are still as prevalent today highlights the 
challenges faced by researchers in this field. 
 
Humans are exposed to complex mixtures of chemicals through various sources including 
occupational settings, the environment, cigarette smoking, vehicular exhaust emissions, 
pharmaceuticals, lifestyle products and foodstuffs. Exposure occurs over a prolonged period of time 
and generally at low levels. Typically this exposure includes a vast assortment of chemicals 
including, but not limited to, polycyclic aromatic hydrocarbons (PAHs), polychlorinated biphenyls 
(PCBs), dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs) and naphthalenes (PCNs), pesticides 
and heavy metals. There is however a significant lack of information available today regarding 
complex mixture toxicology. 
 
A major group of chemicals that are found in complex mixtures are the PAHs, a family of more 
than 1500 compounds (NTP 2012) comprised of two or more fused aromatic rings, found both in 
their native and substituted forms (i.e. methylated, oxygenated or nitrated) (Figure 1). PAHs are 
ubiquitous environmental pollutants that are formed as a result of incomplete pyrolytic processes 
and to which humans are exposed through inhalation, ingestion and dermal absorption. Links 
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between human exposure to complex PAH mixtures and development of diseases including cancer, 
and respiratory and cardiovascular diseases have been described previously (ATSDR 1995; Boffetta 
et al. 1997; IARC 2010; Peters et al. 2001; Pope et al. 2002). Despite their structural similarities, 
PAHs vary greatly in their carcinogenic potency, with both individual and complex mixtures of 
PAHs classified as possible or probable human carcinogens by the International Agency for Cancer 
Research (IARC) (IARC 2010). 
 
Assessment of the carcinogenic risk to humans of exposure to PAHs often involves comparison to 
benzo[a]pyrene (B[a]P) and two approaches are commonly used (Boström et al. 2002; Pufulete et 
al. 2004). In the first approach B[a]P is used as a surrogate marker to determine quantitative risk 
estimates for mixtures of PAHs in air (WHO 2000) or food (EFSA 2008). The second approach is 
component-based in which the potency of different PAHs is expressed relative to that of B[a]P 
(assigned a nominal value of 1). The assigned values for the different PAHs are termed Relative 
Potency Factors (RPF) or Toxic Equivalency Factors (TEF)/Potency Equivalent Factors (PEF). 
Detailed description of the differences between how the factors are derived have been published 
previously (Backhaus et al. 2010; U.S.EPA 2000). An important issue regarding the component-
based approach is that due to a lack of data not all PAHs have been assigned potency values and 
this is likely to lead to a misestimating of the risk. Principles pertaining to how risk assessments 
could be applied to complex PAH mixtures have been proposed (ATSDR 2004; EC 2009; Flowers 
et al. 2002; IPCS 2009; NTP 2012; SCHER et al. 2012; U.S.EPA 2007; U.S.EPA 2010), and indeed 
a recent research proposal testing the health effects of complex PAH mixtures has been approved 
(NTP 2012). However, it is accepted that due a number of limiting factors (discussed in detail 
below) this is likely to lead to misestimating of the risk to human health. 
 
The aim of this paper is to review what is currently known about the effects of interactions between 
PAHs in complex mixtures on mechanisms related to carcinogenesis. We then discuss ways and 
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advantages of studying complex PAH mixtures and how such findings could be applied to future 
risk assessment. 
 
2. Carcinogenic effects of PAHs  
 
The binding of PAHs to DNA and the associated effects that occur as a result is considered the 
major mechanism of PAH-induced mutagenesis and carcinogenesis. Like many chemical 
carcinogens, PAHs require activation through a series of enzymatically-catalyzed reactions to form 
their active metabolites (Conney 1982; Huberman et al. 1976; Sims et al. 1974). The CYP family of 
enzymes, in particular CYP1A1, 1A2 and 1B1, are primarily involved in bioactivation of PAHs to 
their reactive intermediates (Pelkonen and Nebert 1982; Shimada and Fujii-Kuriyama 2004; 
Shimada et al. 1996). Many PAHs are ligands for the aryl hydrocarbon receptor (AhR), which has 
different roles involved in metabolism including regulation of the different bioactivating and 
detoxifying enzymes (Baird et al. 2005; Nebert et al. 2004). For example, B[a]P is activated 
through a three-step enzymatic mechanism involving initial metabolism by CYP enzymes to B[a]P-
7,8-epoxides, followed by conversion to B[a]P-7,8-diols by epoxide hydrolase, and final 
transformation to the ultimate reactive B[a]P-7,8-diol-9,10-epoxide metabolites, again by CYP 
enzymes (Conney 1982). This mechanism of activation has also been shown for other PAHs. An 
additional metabolic pathway is the aldo-keto reductase mechanism that activates PAHs to redox-
active o-quinone derivatives which might also have tumorigenic and mutagenic activities (Park et 
al. 2008; Penning et al. 1999; Zhang et al. 2012). Although many substituted PAHs are also targets 
for CYPs, their bioactivation often involves additional steps. For example, nitrated PAHs (such as 
1-nitropyrene) require initial nitroreduction to primary amines before they are metabolized by CYPs 
to hydroxylamines and activated by conjugation reactions (Chou and Fu 1983; Djuric et al. 1986). 
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The tumorigenic and mutagenic activities of many PAHs have been linked to the ability of their diol 
epoxide (DE) metabolites to bind covalently to exocyclic amino groups on purine bases to form 
either stable bulky PAH-DE-DNA adducts or depurinating adducts which are released from DNA 
leaving abasic sites (Rogan et al. 1993; Sims and Grover 1974; Szeliga and Dipple 1998). Quinones 
can also bind DNA and form stable N2-dG or N2-dA adducts (Penning et al. 1999; Shou et al. 
1993) or depurinating N7-dG adducts (McCoull et al. 1999). PAHs exhibit a large variety in their 
ability to form adducts with DNA which may be a result of different structural conformations. Most 
carcinogenic PAHs contain either a bay or a fjord region within their structure (Figure 1). PAHs 
containing a bay region (i.e. B[a]P) are rigid and planar and their DEs typically react with guanine 
residues, whereas those containing a fjord region (i.e. dibenzo[a,l]pyrene, also known as 
dibenzo[def,p]chrysene) are sterically hindered and non-planar and typically react with adenine 
residues. Studies comparing the biological activity of bay- and fjord-region containing PAHs have 
shown that the latter in general have a higher mutagenic and tumorigenic potential (Dipple et al. 
1987; Jerina et al. 1986; Ralston et al. 1995; Szeliga and Dipple 1998). The variation in potencies is 
most probably associated with the structural differences between adducts and the subsequent effects 
on removal by DNA repair mechanisms (Buterin et al. 2000; Dreij et al. 2005; Kropachev et al. 
2013; Suh et al. 1995). However, it could also be a result of changes in DNA polymerase activity 
and incorrect base-pair insertion resulting from post-lesion DNA synthesis (Broyde et al. 2010; Eoff 
et al. 2010; Huang et al. 2003). 
 
Following bioactivation and reaction with DNA, the PAH metabolites can induce mutations that 
either activate oncogenes or inactivate tumor suppressor genes as part of their carcinogenic 
mechanism. This process can be exacerbated in complex PAH mixtures as they might contain 
compounds that alone have weak carcinogenic potential (e.g. promoters) but in combination with 
initiators act in an additive or more-than additive manner (Baird et al. 2005; U.S.EPA 2007). If 
mutations occur in tumour suppressors this can lead to uncontrolled cell cycle regulation, 
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accumulation of DNA damage and ultimately carcinogenesis. For example, the p53 tumor 
suppressor gene is mutated in many human cancers (Hainaut et al. 1998; Hollstein et al. 1991) and 
exposure to PAHs has previously been associated with mutations in p53 in human lung and breast 
cancers (Hussain et al. 2001; Mordukhovich et al. 2010). The Ras proto-oncogene is mutated in a 
large number of human cancers (Bos 1989; Prior et al. 2012) and associations with PAH exposure 
have been observed in vivo (Gray et al. 2001; Ross and Nesnow 1999). 
 
In addition to the above described mechanisms, generation of reactive oxygen species (ROS) and 
oxidative DNA damage can occur. Induction of oxidative stress is a major mode of toxicity 
associated with airborne particles to which PAHs can be absorbed. This includes responses such as 
formation of oxidative DNA damage, triggering of an inflammatory response and cell death 
(Lodovici and Bigagli 2011). Oxidative DNA damage can result from PAHs undergoing rounds of 
futile redox cycling leading to the formation of 8-oxo-dGuo adducts with subsequent induction of 
mutations (Park et al. 2005; Park et al. 2006). However, it is often very hard to ascertain the 
contribution of oxidative DNA damages on PAH-induced carcinogenesis, in part because such 
damages are formed in parallel with DNA adducts, and thus, to date, the role of oxidative stress in 
PAH mixture toxicology remains unclear.  
 
Pro-carcinogenic epigenetic mechanisms are evidenced as heritable changes that do not involve 
direct modification of the DNA sequence (Esteller 2008; Jones and Baylin 2007). Epigenetic 
changes including DNA methylation and telomere dysfunction have been reported after exposure to 
complex PAH mixtures in human workers and following in vivo mouse exposure (Bollati et al. 
2007; Pavanello et al. 2009; Pavanello et al. 2010; Yauk et al. 2008), and the effects of epigenetic 
changes on PAH-induced carcinogenesis warrants further investigation. 
 
3. Bioactivation of PAH mixtures and reaction with DNA 
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In this section of the review the effects of interactions between PAHs in mixtures and the effects on 
bioactivation (i.e. effects on either expression or activity of metabolic enzymes like CYPs) and 
reaction with DNA (i.e. formation of adducts) is discussed. For this purpose we have sub-divided 
this section into two parts – interactions in binary PAH mixtures and those in complex PAH 
mixtures. To allow for comparisons of interaction effects we have mainly focused on studies that 
have co-exposed and compared effects of individual PAHs (such as B[a]P) with mixtures. 
 
One aspect of the mechanism behind PAH-induced carcinogenesis that will not be discussed in this 
review is analysis of mutagenicity after exposure to complex PAH mixtures. Whilst this is a 
significant area of research for mixture effects, many of the studies have already been extensively 
reviewed in great detail previously (Claxton et al. 2004; Ohe et al. 2004; White 2002; White and 
Claxton 2004). 
 
3.1. Effects of interactions in binary PAH mixtures 
 
Early in vivo studies involved topical exposure of mice to binary PAH mixtures to investigate 
interaction effects on DNA binding (usually formation of B[a]P-DE-DNA adducts) and these are 
summarized in Table 1. Increased binding of B[a]P to DNA in vivo was the more prevalent 
observation following co-exposure of B[a]P with a number of PAHs including benzo[e]pyrene, 
dibenzo[a,e]pyrene, dibenzo[a,l]pyrene, fluoranthene or pyrene (Hughes and Phillips 1990; Rice et 
al. 1988; Rice et al. 1984; Slaga et al. 1979; Smolarek et al. 1987). Conversely, in vivo co-exposure 
of B[a]P with phenanthrene decreased DNA adduct formation (Rice et al. 1984), and with a mixture 
comprised of B[a]P with dibenzo[a,e]pyrene and dibenzo[a,l]pyrene, levels of DNA adducts were 
lower than observed for the individual PAHs (Hughes and Phillips 1990). Furthermore, topical co-
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exposure of 7,12-dimethylbenz[a]anthracene with benzo[e]pyrene decreased binding of the former 
to mouse DNA (DiGiovanni et al. 1982; Slaga et al. 1979; Smolarek et al. 1987).  
 
Whilst the above described studies did not investigate effects on bioactivation, the authors 
concluded that in the presence of different PAHs, activation leading to DNA binding intermediates 
is likely to be altered. In addition, it is also possible that the observed adduct levels in some studies 
could result from interactions affecting the activation of DNA repair systems. More recent in vitro 
and in vivo studies have investigated effects of binary PAH mixtures (Table 1). In in vitro studies 
using human-derived hepatocellular carcinoma (HepG2) cells exposed to binary PAH mixtures, 
increased levels of DNA adducts and expression of CYPs were generally observed compared to 
B[a]P alone (Cherng et al. 2001; Gabelova et al. 2013; Sevastyanova et al. 2007; Staal et al. 2007; 
Tarantini et al. 2011). Whilst the authors of these manuscripts attributed these responses to additive 
or more-than additive effects, only two of the manuscripts based these observations on different 
mathematical models of additivity (Gabelova et al. 2013; Staal et al. 2007) whereas the remaining 
observations were inferred from dose addition effects. Similar effects on CYP-mediated metabolism 
were observed in vivo in male Sprague-Dawley rats exposed to binary PAH mixtures (Bouchard et 
al. 1998) and increased DNA adduct levels have been observed in vitro in hamster embryo cells 
exposed to a mixture of B[a]P and benzo[e]pyrene (Smolarek and Baird 1984). A recent in vitro 
study in human-derived colorectal adenocarcinoma (HT-29) cells observed dose-dependent 
increased fluoranthene metabolism after co-exposure with B[a]P which the authors attributed to 
enhanced CYP-mediated activation of fluoranthene, although neither gene expression or CYP 
activity was measured directly (Harris et al. 2013).  
 
Lower levels of DNA adducts and CYP expression after exposure to binary PAH mixtures have 
been observed in vitro in HepG2 and human embryonic lung (HEL) cells (Binkova and Sram 2004; 
Cherng et al. 2006; Sevastyanova et al. 2007), and whilst the responses in these studies are 
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consistent with less-than additive effects resulting from interactions, no appropriate mathematical 
calculation of additivity was included on which to confirm this. For the former it is likely that these 
contrasting findings in the HepG2 cells result from the use of high PAH concentrations (B[a]P 10 
µM) and related effects on CYP inhibition as a result of elevated ROS formation (Cherng et al. 
2006). For the latter this response probably results from the low metabolic capacity of HEL cells 
and the resulting decrease in PAH activation (Binkova and Sram 2004; Sevastyanova et al. 2007). 
Lower levels of DNA adducts and CYP expression/activity have in general been observed in vitro 
in rat cells (Falahatpisheh et al. 2004; Gabelova et al. 2013; Staal et al. 2008) and in vivo in killifish 
(Willett et al. 2001) and zebrafish (Van Tiem and Di Giulio 2011), and whilst the authors suggested 
these represented  less than additive effects due to interactions, these conclusions were based on 
dose addition observations whereas only two studies applied mathematical modelling (Gabelova et 
al. 2013; Staal et al. 2008). It is possible that these contrasting findings result from  differences 
between human- and experimental animal-derived cells and this conclusion is in agreement with the 
observed variations in sensitivity to TCDD (Silkworth et al. 2005).  However, as the respective 
studies did not use the same test conditions (mixtures, exposure times, concentrations etc.) this 
conclusion regarding species sensitivity cannot fully account for the differences in response and it is 
probable that there are many different sources that contribute to the outcome. 
 
An important caveat to consider for many of the above described studies on binary mixture effects 
in vitro is the used of the human HepG2 cell line. This particular cell line is one of the most 
extensively used for studying the effects of PAHs due to its demonstrated metabolic competency. 
However the result of this widespread use is that the particular cell line likely exists in many 
different clonal variants that might lack the inducibility of particular enzymes involved in 
bioactivation of PAHs. For example, it has been shown that hypermethylation of the CYP1B1 gene 
promoter leads to a lack of induction of CYP1B1 after exposure to dioxin (Beedanagari et al. 2010) 
and this is another consideration that might explain the differences observed in the above described 
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studies. Furthermore this is a consideration that applies to all experimental cell lines and is an 
important reason for maintaining and using cells at low passage numbers to prevent accumulation of 
clonal differences. 
 
In conclusion, the studies on binary PAH mixtures suggest that saturation of activation is an 
important consideration when studying interaction effects, and that the use of experimental models 
plays as important a role as the different mixtures studied. However, as there is a lack of 
consistency between the experimental conditions in the above described studies it is impossible to 
determine the driving source behind the observed differences. Since the described studies do not 
show a consistent effect in response to binary PAH mixtures on DNA damage levels, this suggests 
that formation of DNA damage is an inadequate marker for mixture effects.  
 
3.2. Effects of interactions in complex PAH mixtures 
 
To discuss interaction effects we have focused on studies where exposure to complex PAH mixtures 
has been investigated alongside exposure to individual PAHs. Studies that have investigated 
complex PAH mixtures have typically used two different types: either standard reference materials 
(SRM) or extracts obtained from collected environmental samples. SRMs from the National 
Institute of Standards and Technology have been used: from coal tar (CT, SRM1597, SRM1597a), 
from urban dust (UD, SRM 1649a), from diesel particulate extract (DPE, SRM1650b) and from 
diesel particulate matter (DPM, SRM1975) (May et al. 1992).  
 
Two recently published reviews have extensively discussed transcriptional responses after exposure 
to complex PAH mixtures in vitro and in vivo from original studies and as such these effects have 
not been included (Huang 2013; Sen et al. 2007). Both reviews conclude that in vitro microarray 
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analysis patterns provide a comprehensive approach to assessing effects on gene expression that 
complement animal experiments. 
 
The effects of exposure to SRMs both in vitro and in vivo are summarized in Table 2. Levels of 
DNA adducts in female SENCAR mice exposed in vivo to CT or UD with either B[a]P or 
dibenzo[a,l]pyrene decreased compared to the individual PAHs alone, although there was no clear 
correlation between adduct levels and change in CYP expression (Courter et al. 2007a; Marston et 
al. 2001). Similarly, lower levels of DNA adducts were observed in vitro in human-derived breast 
adenocarcinoma (MCF-7) cells and Chinese-hamster-derived lung fibroblast (V79) cells exposed to 
CT, UD or DPE with either B[a]P or dibenzo[a,l]pyrene (Mahadevan et al. 2005a; Mahadevan et al. 
2005b; Mahadevan et al. 2007; Musafia-Jeknic et al. 2005). The decreases in DNA adduct levels are 
probably a result of increased competition for substrate binding to activating enzymes. In contrast, 
DNA adduct levels increased in female SENCAR mice exposed in vivo to DPE with either B[a]P or 
dibenzo[a,l]pyrene compared to the individual PAHs alone although again there was no clear 
correlation between adduct levels and change in CYP expression or activity (Courter et al. 2008). 
This difference in DNA adduct formation may be attributable to the higher amounts of DPE (50 
mg) these mice were exposed to compared to the amount of either CT or UD (1 mg). It is also 
plausible that different PAHs in the DPE could be causing additive or more-than additive effects on 
DNA adduct formation, although in human-derived MCF-10A cells in vitro co-exposure of DPE 
with B[a]P caused decreased levels of DNA adducts compared to B[a]P alone, and co-exposure 
with dibenzo[a,l]pyrene caused no significant change (Courter et al. 2007b). Taken together these 
findings suggest that the response to complex PAH mixtures is likely attributable to inhibitory 
effects on activation resulting from particular PAHs in the mixture and potentially also the effects 
of metabolic enzyme saturation leading to less than additive effects although this was not 
mathematically modelled. Similar to the above described binary studies, these studies also suggest 
that DNA damage formation might not be a good marker for mixture effects.  
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To discuss the effects of interactions we have focused on studies that have co-exposed mixtures 
with individual PAHs and compared the effects. There is however a number of recent studies that 
have investigated the effects of exposure to complex PAH mixtures on DNA adduct formation 
compared to exposure to individual PAHs (without co-exposure). Exposure of human-derived 
BEAS-2B or MCF-7 cells or HEL cells in vitro to either SRMs or environmental PAH mixture 
extracts typically resulted in decreased levels of DNA adducts compared to B[a]P alone, although it 
is not always entirely clear the motivation for the choice of mixture concentration and it is plausible 
these decreases are reflective of the use of different concentrations (i.e. higher B[a]P when used 
alone than what is in the mixtures) (Binkova and Sram 2004; Kuljukka-Rabb et al. 2001; Oh et al. 
2011; Pohjola et al. 2003; Rossner et al. 2013; Sevastyanova et al. 2007). Similarly, in vitro 
exposure of rat-derived WB-F344 cells or in vivo exposure of female FVB/N mice to complex PAH 
mixtures resulted in decreased levels of DNA adducts compared to B[a]P alone (Andrysik et al. 
2011; Siddens et al. 2012). These findings suggest that interactions in complex PAH mixtures 
typically lead to less-than additive effects, similar to what was observed in the in vivo co-exposure 
experiments (Courter et al. 2008; Courter et al. 2007a; Marston et al. 2001). However, in in vitro 
studies using HepG2 cells increased DNA damage (both adducts and strand breaks) was observed 
after exposure to complex PAH mixtures suggesting additive/more-than additive effects of 
interactions (Niziolek-Kierecka et al. 2012; Sevastyanova et al. 2007; Tarantini et al. 2009). 
However, for both scenarios the assumptions of interaction effects are based on dose addition 
observations and were not determined mathematically. This is in agreement with the results 
obtained using binary PAH mixtures in HepG2 cells and probably reflects the metabolic 
competency of these cells (Knasmuller et al. 1998). Whilst interaction effects are not possible to 
determine and the proposed conclusions regarding additivity are based on simple dose addition 
observations, these studies show decreased levels of adducts with mixtures than with B[a]P which 
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is in agreement with the above described co-exposure experiments indicating that analysis of B[a]P 
alone is not sufficient as a surrogate for mixture effects. 
 
In conclusion, the observed effects resulting from exposure to complex PAH mixtures are similar to 
what was observed with binary PAH mixtures in that the response was dependent on many different 
contributory factors including the test system and mixtures assessed, and was not predictable from 
comparison to individual PAHs. However, similar to the conclusion from the binary studies the lack 
of coherence between the experimental conditions makes it impossible to determine the overall 
driving source of the responses. 
 
4. Carcinogenicity of PAH mixtures 
 
4.1. PAH exposure and cancer in humans 
 
High exposures to PAHs in occupational settings are of significant risk to humans. Accordingly, 
IARC lists B[a]P and a number of industrial complex PAH mixtures including coal tars, mineral 
oils, shale oils and soot and exposure through cigarette smoke, aluminium production, coal 
gasification and coke production as carcinogenic to humans (IARC 2010). In addition, there are a 
number of individual PAHs and mixtures/exposures classified as groups 2A (probably 
carcinogenic) and 2B (possibly carcinogenic) (IARC 2010). Case-control studies on human workers 
exposed to PAHs through their occupation and also through dietary exposure have been extensively 
described previously (Boffetta et al. 1997; Bosetti et al. 2007; IARC 2010). From the case control 
studies human cancers associated with occupational exposure were observed in a large number of 
sites including the respiratory system, larynx, bladder, esophagus/stomach, skin and kidney. The 
most prevalent form of cancer from occupational exposure to complex PAH mixtures was found in 
the lungs (Boffetta et al. 1997; Bosetti et al. 2007; IARC 2010). 
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In addition to the above described occupational risk, a large number of factors have been linked to 
exposure to complex PAH mixtures and cancer. These include smoking, cooking and dietary intake 
and wood burning. Tobacco smoking is considered the overwhelming cause of lung cancer in 
humans and is associated with approximately 90 % of all lung cancer incidences and 1.2 million 
deaths per year worldwide (DeMarini 2004; IARC 2004). In addition, smoking has been identified 
as a cause of cancer in a number of other human organ sites (IARC 2004). B[a]P was one of the 
first carcinogenic compounds detected in tobacco smoke, and the links between tobacco smoking, 
B[a]P and DNA damage have been reviewed recently (Alexandrov et al. 2010). Dietary exposure to 
complex PAH mixtures is also a significant risk for human cancer development (Phillips 1999), and 
moreover, is the primary route of non-occupational exposure for non-smokers. A number of human 
cancers have been associated with dietary intake of complex PAH mixtures including colorectal, 
pancreatic and prostate (IARC 2010). In addition to food consumption, cooking has also been 
linked to development of human cancer. Investigations in the county of Xuan Wei, China, showed 
unusually high levels of lung cancer mortality rates. In this area, residents (particularly women) are 
exposed to high levels of unvented smoke from indoor cooking resulting in high level and chronic 
exposure to complex PAH mixtures which was highly associated with lung cancer development 
(Chuang et al. 1992; DeMarini et al. 2001). More work is required to fully understand the cellular 
mechanisms involved in carcinogenesis but it is evident that exposure to PAHs in all these scenarios 
is a major contributor to the observed cancers. 
 
4.2. Carcinogenic effects of PAH mixtures in experimental animals 
 
In the two-stage model tumors can be induced by application of an initiator (carcinogenic PAH, 
sub-threshold dose) followed by repetitive exposure to a promoter (Mason et al. 1990; Nesnow et 
al. 1983). Over 100 PAHs and their metabolites are known to be tumor initiators or complete 
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carcinogens in the mouse skin two-stage model (Nesnow et al. 1983; Pereira 1982) with the 
consequence that interactions most likely alter the response to complex PAH mixtures compared to 
individual PAHs.  
 
Studies on binary PAH mixtures have shown that weak or non-carcinogenic PAHs have various 
influences on the tumor-initiating activities of PAHs with stronger carcinogenic potential (Table 1). 
Dermal exposure of mice to B[a]P with various PAHs caused an increase in tumor initiation which 
correlated with increased DNA binding. Conversely, dermal co-exposure of 7,12-
dimethylbenz[a,h]anthracene with the same PAHs caused a decrease in tumor initiation which 
correlated with decreased 7,12-dimethylbenz[a,h]anthracene binding to DNA (DiGiovanni et al. 
1982; Slaga et al. 1979). It was suggested that the co-exposed PAHs might be affecting the 
metabolism to DNA-reactive metabolites. In a dose-response study performed in mice it was found 
that quintary PAH mixtures exhibited more than additive effects at low doses and less than additive 
effects at high doses when lung adenomas were scored compared to individual PAH exposure 
(Nesnow et al. 1998). This paradoxical finding (i.e. non-linear dose-effect relationship) probably 
results from competitive inhibition of the metabolizing enzymes and hence decreased amounts of 
DNA-reactive metabolites and fits with the findings of the above described studies on binary and 
complex PAH mixtures.  
  
Tumor induction resulting from exposure to complex PAH mixtures has been studied in vivo using 
a number of different exposure routes including oral (Culp et al. 1998; Goldstein et al. 1998; 
Weyand et al. 1995), gavage (Robinson et al. 1987), dermal (Deutsch-Wenzel et al. 1984; Grimmer 
et al. 1985; Grimmer et al. 1983; Grimmer et al. 1982; Nesnow et al. 1983) and lung implantation 
(Grimmer et al. 1988; Grimmer et al. 1987a; Grimmer et al. 1987b; Grimmer et al. 1984). A review 
by Schneider et al. (2002) of some of these earlier tumor induction studies concluded that the 
contribution of B[a]P to the overall potency of the PAH mixtures depends on the route of exposure 
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and the end-point studied (i.e. the cancer type) (Schneider et al. 2002). More recent studies using 
the dermal tumour initiation mouse model and co-exposure of complex PAH mixtures with either 
B[a]P or dibenzo[a,l]pyrene are summarized in Table 3 with the reported effects on numbers of 
tumors per tumor bearing animal (TBA) as an indicator of response (Courter et al. 2008; Courter et 
al. 2007a; Marston et al. 2001). One important conclusion was that the formation of DNA adducts 
in the skin (after single administration) did not predict the final tumor response suggesting that 
DNA adduct formation is a poor marker for tumorigenesis induced by complex PAH mixtures. 
 
In these studies when the complex PAH mixtures were co-exposed with either B[a]P or 
dibenzo[a,l]pyrene increased numbers of tumour/TBA were observed compared to the mixture 
alone, whereas no effect or decreased numbers of tumors/TBA were observed when compared to 
exposure to B[a]P or dibenzo[a,l]pyrene alone (Table 3). Taken at face value these findings seem to 
suggest that the effects on tumors/TBA are solely governed by the application of the individual 
PAHs. In the study published by Siddens et al. (2012) these discrepancies were discussed in the 
context of RPF values and how using values from the U.S. EPA the RPF value for a mixture of 
DPM and CT would be 0.34 µg B[a]P-equivalent (B[a]Peq). In comparison to B[a]P, which was 
used at 100 µg, it would be predicted that the mixtures would elicit a much weaker tumor response. 
However, their results showed no differences in incidence, latency, multiplicity or tumor type 
between the two exposures showing that the observed tumor effects in response to the complex 
mixture were higher than anticipated based on current RPF values (Siddens et al. 2012). It should 
however be considered that not all PAHs in the mixtures tested would have been assigned RPF 
values due to the lack of experimental data which could lead to misestimating of the mixture 
potency. 
 
Using a similar approach we calculated the corresponding B[a]Peq values of the CT, DPE and UD 
mixtures used in three recent mice studies (Courter et al. 2008; Courter et al. 2007a; Marston et al. 
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2001). The RPF values were 0.23, 0.28 and 0.015 µg B[a]Peq respectively, to be compared with the 
50.4 µg B[a]P used and in stark difference to the observed numbers of tumors/TBA which differed 
around a factor of 3. These results support the observation from Siddens et al. (2012) that much 
weaker responses than were observed would be predicted, and highlights the inadequacy of the 
current RPF system for complex PAH mixtures which is further discussed below. 
  
5. Risk assessment of complex PAH mixtures 
 
5.1. Risk assessment approaches for PAHs  
 
Cancer risk assessment of PAHs typically encompasses three approaches – B[a]P as a surrogate 
marker for mixture exposure, the use of component-based factors (such as RPF and TEF values) or 
the comparative potency approach (Flowers et al. 2002; IPCS 1998; Pufulete et al. 2004). The first 
approach has been applied to determine risk of exposure to PAHs in air (WHO 2000) and by the 
European Food Safety Agency (EFSA) as a marker for PAH levels in foods (EFSA 2008). EFSA 
further investigated the use of mixtures of other PAHs (PAH4 and PAH8) and concluded these were 
more appropriate markers of PAH exposure in foodstuffs (EFSA 2008). However, the necessary 
assumption that relative PAH concentrations will remain stable between different exposure 
scenarios is a major weakness for ubiquitous PAH mixtures and both agencies concluded that the 
surrogate marker approach is likely to misestimate the actual risk of exposure to humans. In the 
second approach the different components of the PAH mixtures (where identifiable) are assigned 
potency factors relative to B[a]P (i.e. RPF or TEF values) and from these factors cancer risk 
estimates for PAH mixtures can be derived. Risk estimates are determined by calculating and 
summing B[a]Peq values for the different PAHs in the mixtures, and as described above, this can be 
limited by a lack of potency values for all PAHs. To adjust for possible adverse effects resulting 
from interactions uncertainty factors (or safety factors) are often included in risk assessments 
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(ECETOC 2003; ECETOC 2010; KEMI 2003; Martin et al. 2013). The final approach assesses the 
whole PAH mixture by estimating the potency without having to identify or quantify individual 
PAH compounds. Using a source-specific PAH mixture which has been thoroughly characterized in 
epidemiological and biological studies as a reference, a second sufficiently similar PAH mixture is 
ranked based on its comparative potency in the biological test. This approach has been suggested 
for a variety of complex PAH mixtures (Albert et al. 1983; Lewtas 1985), although to the authors’ 
knowledge, has yet to be implemented by regulatory agencies. In the following section the 
limitations of these approaches to complex PAH mixture risk assessment are discussed and then an 
alternative approach based on whole mixture assessment is presented. 
 
5.2. Limitations of the current approaches for PAH mixture risk assessment 
 
Risk assessment of complex PAH mixtures is a challenging issue. As discussed throughout this 
review there is a growing consensus that the current approaches to risk assessment are insufficient. 
The weaknesses of these approaches regarding complex PAH mixture assessment are outlined 
below. 
 Ubiquitous nature of complex PAH mixtures: The composition of complex PAH mixtures in 
the environment varies significantly depending on location sampled, time/season of 
sampling and surrounding industrial and vehicular use. This means that analysis of a 
surrogate PAH (i.e. B[a]P) for whole mixtures is unreliable when predicting human risk. An 
option to restrict this limitation has been suggested involving identification of typical PAH 
profiles or “fingerprints‟ correlated to the different sources (Howsam and Jones 1998; 
Ravindra et al. 2008; Tobiszewski and Namieśnik 2012). 
 Lack of a common mechanism for PAHs: For the component-based approach (i.e. using RPF 
or TEF values) to be valid for complex PAH mixture risk assessment it requires a common 
mode of action and observed additivity in the resulting toxicological effect. The 
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heterogeneous mechanisms that are likely to occur for different PAHs (Boström et al. 2002) 
predispose that this is not the case, and the many studies described in this review 
demonstrating non-additive effects (both more- and less-than) arising from interactions 
confirm this. 
 Disparity between TEF/RPF values for individual PAHs: For the majority of PAHs data 
regarding their potency is lacking and therefore many PAHs have not been assigned potency 
values. A range of RPF or TEF values from 8 different published scales (Collins et al. 1998; 
EPA 2004; Kroese et al. 2001; Larsen and Larsen 1998; Malcolm and Dobson 1994; Muller 
1997; Nisbet and LaGoy 1992; U.S.EPA 2010) is given in Table 4. It is evident from the 
ranges that there are significant variations in the assigned factors depending on which test 
systems they are based on that will be reflected when calculating B[a]Peq values for 
mixtures and is likely to misestimate the risk, in agreement with earlier conclusions about 
the limitations of equivalency factors (Gaylor et al. 2000; Schneider et al. 2002). 
Dibenzo[a,l]pyrene is a very good example of this as depending on the scale used the factor 
can vary between 1 and 100 (Table 4) and has recently been suggested to be even higher 
(Siddens et al. 2012). Similarly, dibenz[a,h]anthracene ranges from 0.1 – 10 suggesting that 
it is either ten-fold more or less potent than B[a]P (Table 4). In many cases these differences 
can be attributed to the derivation of values from different experimental exposures and 
cancer studies. However, it remains that the lack of coherence between the different scales is 
a major limitation for risk assessment.  
 
One of the biggest issues for risk assessment of mixtures of PAHs is the dearth of information 
available. This lack of information has been highlighted by both the EU and the U.S. EPA as being 
a significant issue (EC 2009; U.S.EPA 2000). A prioritization of data needs and collection of 
reliable and relevant data for risk assessment is critical to overcome this issue and a number of 
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considerations have been discussed by these agencies previously. Some of the most important 
considerations are outlined below: 
 The need to identify and characterize whole mixtures more extensively and the adoption of 
procedures to model various human exposure scenarios. Better characterization of the 
individual PAHs in mixtures is important for understanding their contribution to the mixture 
and assignment of potency values to more PAHs in mixtures would improve component-
based risk assessment strategies (although this should not predispose risk assessment away 
from whole mixture analysis). 
 Shift towards assessment of whole mixture effects and exposure, including chemicals with 
dissimilar structures and modes of action. More empirical evidence of the joint action of 
environmental mixtures would pre-dispose towards more sensitive and accurate risk 
assessment and likely challenge the rule of thumb assumption that dose addition is sufficient 
for predicting risk. 
 Improvement of the dose-response methods for modelling risk including development of 
stringent methods for validating these. These models should be robust to include all 
interaction effects and not just dose addition. 
 In many cases mixtures of PAHs have been chosen to suit certain experimental conditions 
leading to a trend in studying mixtures with known/similar effects and a lack of information 
on chemicals that alone do not induce effects but can act to modulate toxicity. Future 
assessment would be better suited by including these chemicals 
 Current risk assessment methods tend towards a single risk estimate. A priority towards risk 
estimate based on exposure ranges would be more appropriate, ideally reflecting different 
risk analysis methods for the particular mixtures and thus allowing for incorporation of 
uncertainties associated with method choice. 
 
5.3. Risk assessment of complex mixtures of PAHs based on whole mixture assessment 
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Although the component based approach is recommended and mostly used by both the US and EU 
authorities, the implementation of a whole mixture based approach is necessary in order to account 
for possible interaction effects. This has previously been recognized by the U.S. EPA (Flowers et al. 
2002; U.S.EPA 2000) and more recently by the US National Toxicology Program (NTP) which has 
approved a research program aiming to increase the knowledge of complex PAH mixture toxicity 
(NTP 2012). This approach has so far not been a viable option mainly because of limited data for 
establishing reference mixtures and methods for determining sufficient similarity. 
 
A potential alternative would be to use mixture assessment factors (MAFs) similar to those that 
have been discussed previously (Backhaus et al. 2010). In a report for the Swedish Chemicals 
Agency an approach was discussed outlining how a MAF could be used to reflect a default 
exposure scenario through single substance assessment for situations where mixtures are present 
with neither a defined chemical composition (i.e. where it is impossible to ascertain the different 
components and respective amounts) and where quantitative knowledge regarding individual 
component toxic potencies is lacking (Backhaus et al. 2010). MAFs, similar to the comparative 
potency approach, differ to component-based approaches in that they do not rely on individually 
assigned potency values compared to a reference compound but instead compare the effects of 
whole mixtures on a relevant biological endpoint. However, in contrast to the comparative potency 
approach, the MAFs do not rely on a well characterized and sufficiently similar reference mixture 
but instead on using a well characterized single PAH (i.e. B[a]P). 
 
We have recently investigated the potential of using activation of DNA damage signaling as a 
biological end-point for developing MAFs (Jarvis et al. 2013; Niziolek-Kierecka et al. 2012). DNA 
damage signaling governs the detection of damage and downstream activation of cell cycle arrest, 
DNA repair and/or cell death and thereby plays an important role in the response to carcinogens 
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(Figure 2). Using DNA damage signaling for studying mixtures also has the advantage that whilst 
the different types of DNA damage induced by PAHs have different kinetics of formation, activate 
different repair processes, and demonstrate different efficiencies for repair, they share a common 
DNA damage signaling network directing all of these processes (Ciccia and Elledge 2010; Sancar et 
al. 2004). 
 
DNA damage signaling results from activation of Ataxia telangiectasia mutated (ATM), ataxia 
telangiectasia and Rad3-related protein (ATR) or DNA-dependent protein kinase (DNA-PK). 
Activation of ATM and DNA-PK is commonly attributed to DNA double strand breaks whereas 
activation of ATR results from single stranded DNA (Lovejoy and Cortez 2009). Two proteins that 
are activated downstream (by phosphorylation) in the response to the different types of damage are 
Checkpoint kinase 1 (Chk1), a kinase involved in cell cycle regulation (Zeng et al. 1998; Zhao and 
Piwnica-Worms 2001) and H2A histone family member X (H2AX), a core histone protein 
maintaining genomic stability (Fernandez-Capetillo et al. 2004; Rogakou et al. 1998). 
Phosphorylation of H2AX is an established marker for DNA damage (Fernandez-Capetillo et al. 
2004; Mah et al. 2010) and recent studies of the role of phosphorylated Chk1 in the DNA damage 
signaling network have confirmed its potential as a marker (Dai and Grant 2010; Ma et al. 2011; 
Patil et al. 2013). Both proteins have been shown as markers of DNA damage in vivo (Bauer et al. 
2011; Bauer et al. 2012) and furthermore have been shown to be activated in response to single and 
double strand breaks, bulky DNA adducts and oxidative DNA damage, all of which are induced by 
PAHs as described above (Bihari and Fafandel 2004; Mattsson et al. 2009; Park et al. 2005; Park et 
al. 2006; Rogan et al. 1993; Szeliga and Dipple 1998; Tung et al. 2014). It is considered that the 
different types of DNA damage could give rise to different patterns of activation of DNA damage 
signaling and hence different response proteins. Thus, it is likely necessary that for more accurate 
risk assessment analysis of more than one marker might be required to cover all the different 
possible patterns of activation. 
25 
 
 
Recently it has been  demonstrated that both Chk1 and H2AX are efficiently phosphorylated in 
response to DNA damage following exposure to low levels of environmental mixtures of PAHs 
(Jarvis et al. 2013; Mattsson et al. 2009; Niziolek-Kierecka et al. 2012). In a study exposing HepG2 
cells to nanomolar concentrations of PAHs extracted from urban air PM persistent phosphorylation 
of Chk1 and H2AX was observed at B[a]Peq concentrations of 1 and 8 nM respectively (Jarvis et al. 
2013) showing that these markers are sensitive for low levels of DNA damage. Using B[a]P as a 
reference compound the results suggested that the mixture was at least 100 times more potent at 
B[a]Peq concentrations than exposure to B[a]P alone (Jarvis et al. 2013). This is in line with the in 
vivo studies discussed above (Courter et al. 2008; Courter et al. 2007a; Marston et al. 2001; Siddens 
et al. 2012) and suggests that phosphorylation of Chk1 and H2AX could serve as biological end-
points for developing MAFs. Further work is required to investigate the effects of exposure to low-
levels of DNA damaging compounds and whether the induction of these markers correlates with 
results obtained from animal studies.  
 
5.4. Limitations of the current approaches for PAH mixture risk assessment 
 
Risk assessment based on whole mixtures is proposed to be more appropriate in future for 
determining the risks of exposure to PAH mixtures on human health. However, there are a number 
of issues that have to be considered as outlined below: 
 It is impossible to test all mixtures in animal studies. From both an ethical and a practical 
perspective it is not possible to perform animal studies for every mixture. Analysis of the 
effects of similar mixtures is a potential way to avoid this issue but that approach is not 
viable for scenarios where mixture composition changes. 
 Challenge to determine what the mixture will be compared against. As environmental 
mixtures are comprised of many different chemical classes it is a challenge to determine 
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how the whole mixtures will be compared experimentally. For example, comparison to 
B[a]P is only sufficient for the PAH component of the mixture. Furthermore a reliable 
biological endpoint is required for whole mixture assessment and, although we discuss 
above how DNA damage signalling is a possibility, it remains to be determined what 
marker(s) would be most appropriate. 
 Chemical characterization is costly and difficult. Whilst it is not fundamentally needed for 
all whole mixture based risk assessment strategies the characterization of the chemical 
mixtures for use as a reference mixture (for example in the comparative potency approach) 
is difficult for a number of reasons including lack of analytical information on individual 
PAHs for characterization and overlapping of molecular signatures making it hard to 
analyze low-level PAHs or PAHs with increasing ring numbers. 
 Whole mixture assessment does not permit experimental analysis of chemical modes of 
action. For the purpose of risk assessment this aspect is arguably less important than the 
above issues. However, important for experimental research is a need to understand the 
mode of action of chemicals and this is impossible to determine in mixtures, only the mode 
of action of the mixture is testable. 
 
6. Conclusions and future challenges for complex PAH mixture risk assessment 
 
Determining the health risks to humans of exposure to complex PAH mixtures is profoundly 
challenging and a daunting task. In this review we have described the current status of the field of 
mixture effects with regards to PAHs in vitro and in vivo, and why the current approaches for risk 
assessment are scientifically limited and likely to misestimate the actual risk to human health.  
 
One of the biggest issues for understanding complex PAH mixture toxicity is that it is impossible to 
test all mixtures in animal models and cultured cell lines. It is widely accepted that both approaches 
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have limitations that restrict their extrapolation to human exposures, but at present they remain the 
best tools for experimental research. It is evident from the studies described in this review that the 
observed responses to complex PAH mixtures are dependent on the modeling system used. Similar 
to what the Toxicity Testing in the 21
st
 Century program promotes (NRC 2007; Schmidt 2009) and 
NTP has recently given approval for (NTP 2012), in the future a combination of different 
approaches to evaluating complex PAH mixture effects should be used alongside animal models 
and cultured cell lines to better understand the effects of interactions. This combination could 
include other approaches such as tissue models generated in bioreactors and human induced 
pluripotent stem cells, and also in silico modeling, although much more work is required to 
understand how these can be successfully integrated into risk assessment. 
 
In addition to robust modeling systems, it is necessary to identify reliable, sensitive and relevant 
markers for risk assessment of complex PAH mixtures which importantly are quantifiable in 
different experimental settings. The analysis of PAH activation (by CYPs) and study of DNA 
adduct formation have demonstrated wide variation in the response to complex PAH mixtures (see 
above described studies) showing they are poor markers for mixture effects. At this point it remains 
unclear what other markers would be appropriate, though the inclusion of analysis of activation of 
DNA damage signaling would appear to be compatible. 
 
Finally, the emphasis needs to be switched to studying real life mixtures. It is clear from the above 
described studies that binary PAH mixture assessment, whilst allowing for general experimental 
analysis of effects, represents a poor surrogate for studying mixture effects in relation to human 
risks. An important change for the future and one which has taken precedent in more recent 
analyses is to investigate the effects of complex PAH mixtures, ideally mixtures that are extracted 
from actual environmental samples such as urban air and soil. It is important that risk assessment 
focuses on whole mixtures allowing for the effects of interactions to be included. A greater 
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identification of the different chemicals in the mixtures would be beneficial for understanding 
deposition and human exposure, but should not predispose risk assessment towards component-
based analyses. 
 
In conclusion, it is apparent that there are significant challenges to overcome to implement reliable 
and accurate risk assessment of complex PAH mixtures. Paramount to this is implementation of 
analyzing relevant mixtures that reflect actual human exposure. It is important to consider that 
today no one single approach is reliable or acceptable and that a combination of different techniques 
and strategies is required. Finally, a concerted effort on behalf of the researchers and the regulatory 
agencies is required to develop more intelligent and systematic approaches to mixture-based risk 
assessment. 
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Figure Legends 
 
Figure 1. Examples of some commonly studied PAHs (A) and substituted PAHs (B). The bay and 
fjord regions are indicated by arrows. 
 
Figure 2. DNA damage signalling coordinates the genotoxic insults caused by complex PAH 
mixtures. A large variety of DNA damages including strand breaks, adduct formation, oxidative 
damage and abasic sites resulting from depurinating damages occur following exposure to complex 
PAH mixtures. Central to the response to these damage stimuli is DNA damage signalling. 
Tolerable DNA damage can lead to downstream responses including cell cycle arrest and DNA 
repair, whereas excessive/irreparable DNA damage can lead to apoptosis. Both scenarios are 
considered positive responses as they prevent the carcinogenic process. Mutations can occur as a 
result of unrepaired or wrongly repaired DNA damage or errors in signal transduction and are a 
negative outcome as they promote and accelerate the carcinogenic process. The pivotal role that 
DNA damage signalling plays in coordinating the DNA damage response makes it an appropriate 
biological endpoint for whole mixture assessment. 
 
Table 1: Summary of the effects on CYP450s and DNA adduct formation after in vivo and in vitro exposure to binary PAH mixtures compared to individual PAH effects 
 
Test System PAH Mixture Dose Route 
CYP450s 
Adduct Levels Reference 
Studied EROD Effect 
In vivo studies 
Female CD-1 Mice 
B[a]P:B[e]P/PYR/FLU 200a:100b Topical    + 
Slaga et al. 1979 
DMBA:B[e]P 10a:100b Topical    - 
B[a]P:FLU/PYR 15-22a:171-183a Topical    + Rice et al. 1984 
B[a]P:FLU 11a:110a Topical    + Rice et al. 1988 
Female SENCAR Mice 
B[a]P:B[e]P 200:20-200a Topical    = 
DiGiovanni et al. 1982 
DMBA:B[e]P 20:20-200a Topical    + 
B[a]P:B[e]P 50-200:50-2000a Topical    + 
Smolarek et al. 1987 
DMBA:B[e]P 5-20:5-400a Topical    - 
Male Parkes Mice 
DB[a,l]P:B[a]P/DB[a,e]P 500:500a Topical    = 
Hughes and Phillips 1990 B[a]P:DB[a,e]P 500:500a Topical    + 
DB[a,l]P:B[a]P:DB[a,e]P (tertiary mixture) 500:500:500a Topical    - 
Male Sprague-Dawley Rats 
PYR:B[a]P 5:0.5-25c i.v.  No + (met)  
Bouchard et al. 1998 
PYR:NAP 5:0.5-25c i.v.  No + (met)  
Fundulus heteroclitus B[a]P:FLU 5:5-50d i.p. 1A Yes - (act) +, - Willett et al. 2001 
Danio rerio B[k]F:FLU 50:150e  1A, 1B1, 1C1 Yes + (exp), - (act)  Van Tiem and Di Giulio 2011 
In vitro studies 
HepG2 cells (human) 
B[a]P:B[ghi]P 1:0.1-10f  1A1 No + (exp) + Cherng et al. 2001 
B[a]P:1-NP 10:2.5-10f  1A1 No - (exp) - Cherng et al. 2006 
B[a]P:B[b]F/DB[a,h]A/DB[a,l]P/1-MP 3:3/1/0.1/30f  1A1/2, 2B6 No + (exp) + 
Staal et al. 2007 
B[a]P:FLU 3:30f     + 
B[a]P:B[a]A/B[b]F/B[ghi]P/CHR/DB[a,h]A/IP 1:1f     + 
Sevastyanova et al. 2007 
B[a]P:B[k]F 1:1f     - 
B[a]P:B[b]F/DB[a,h]A/IP 1:1f     + 
Tarantini et al. 2011 B[a]P:B[k]F 1:1f     - 
B[a]P:B[a]A/B[ghi]P/CHR/FLU/PYR 1:1f     = 
B[a]P:DB[c,g]C 0.01-1:1f  1A1 No + (exp) +, - Gabelova et al. 2013 
Embryonic lung cells (human) 
B[a]P:B[a]A/B[b]F/B[k]F/B[ghi]P/CHR/DB[a,h]A/IP 1:1f     - 
Binkova and Sram 2004 
DB[a,l]P:B[a]A/B[b]F/B[k]F/B[ghi]P/CHR/DB[a,h]A/IP 0.1:0.1f     - 
B[a]P:B[a]A/B[b]F/B[k]F/B[ghi]P/CHR/DB[a,h]A/IP 1:1f     - Sevastyanova et al. 2007 
HT-29 cell (human) FLU:B[a]P 1-25:1-25f   No + (met)  Harris et al. 2013 
Rat kidney cells 
B[a]P:CHR 0.03-30:3f  1A1, 1B1 Yes - (exp), - (act)  
Falahatpisheh et al. 2004 
B[a]P:ANT 0.03-30:3f  1A1, 1B1 Yes + (exp), - (act)  
WB-F344 cells (rat) B[a]P:DB[c,g]C 0.01-1:1f  1A1 No - (exp) - Gabelova et al. 2013 
Precision-cut rat liver slices 
B[a]P:B[b]F/DB[a,h]A/DB[a,l]P 3:10/10/0.3f  1A2  No - (exp) - 
Staal et al. 2008 
B[a]P:FLU 3:30f  1A2 No + (exp) + 
DB[a,h]A:DB[a,l]P/FLU 10:0.3/30f  1A2 No - (exp) - 
All mixtures   1A1 No + (exp)  
Hamster embryo cells B[e]P:B[a]P 0-5a:11.2-18.9b     + Smolarek and Baird 1984 
 
Abbreviations: 1-MP, 1-methylphenanthrene; 1-NP, 1-nitropyrene; act, EROD activity; ANT, anthracene; B[a]A, benz[a]anthracene; B[a]P, benzo[a]pyrene; B[b]F, benzo[b]fluoranthene; B[e]P, benzo[e]pyrene; B[ghi]P, 
benzo[ghi]perylene; B[k]f, benzo[k]fluoranthene; CHR, chrysene; DB[a,e]P, dibenzo[a,e]pyrene; DB[a,h]A, dibenz[a,h]anthracene; DB[a,l]P, dibenzo[a,l]pyrene; DB[c,g]C, dibenzo[c,g]carbazole; DMBA, 7,12-
dimethylbenz[a]anthracene; exp, gene expression; FLU, fluoranthene; i.p., intraperitoneal; i.v., intravenous; IP, indeno[123-cd]pyrene; met, metabolism; NAP, naphthalene; PYR, pyrene 
 
Symbol guide: a, nmol; b, µg; c, µmol/kg; d, mg/kg; e, µg/L; f, µM; +, increase compared to PAH alone; -, decrease compared to PAH alone; =, no observed difference in effect compared to PAH alone; 
Table 2: Summary of the effects on CYP450s and DNA adduct formation after in vivo and in vitro co-exposure to complex PAH mixtures compared to individual PAH effects 
 
Test System PAH Mixture Dose Route 
CYP450s 
Adduct Levels Reference 
Studied EROD Effect 
In vivo studies 
Female SENCAR Mice 
B[a]P:CT 200a:1b Dermal 1A1, 1B1 No + (exp) - 
Marston et al. 2001 
DB[a,l]P:CT 2a:1b Dermal 1A1, 1B1 No + (exp) - 
B[a]P:UD 200a:1b Dermal 1A1, 1B1 No - (exp) - 
Courter et al. 2007a 
DB[a,l]P:UD 200a:1b Dermal 1A1, 1B1 No - (exp) - 
B[a]P:DPE 200a:50b Dermal 1A1, 1B1 No - (exp), - (act) + 
Courter et al. 2008 
DB[a,l]P:DPE 2a:50b Dermal 1A1, 1B1 No + (exp), = (act) + 
In vitro studies 
MCF-7 Cells (Human) 
B[a]P:CT 80a:400c  1A1, 1B1 No = (exp) - 
Mahadevan et al. 2005b 
DB[a,l]P:CT 0.8a:400c  1A1, 1B1 No + (exp) - 
B[a]P:UD 80a:400c  1A1, 1B1 Yes + (exp), - (act) - 
Mahadevan et al. 2005a 
DB[a,l]P:UD 0.8a:400c  1A1, 1B1 Yes + (exp), - (act) = 
B[a]P:UD 10:400c  1A1, 1B1 Yes + (exp), = (act) - 
Musafa-Jeknic et al. 2005 
DB[a,l]P:UD 0.1:400c  1A1, 1B1 Yes + (exp), + (act) - 
MCF-10A Cells (Human) 
B[a]P:DPE 80a:400c  1A1, 1B1 Yes = (exp), = (act) - 
Courter et al. 2007b 
DB[a,l]P:DPE 0.8a:400c  1A1, 1B1 Yes +/= (exp), +/= (act) = 
V79 Cells (Chinese Hamster) 
B[a]P:CT 80a:400c     - 
Mahadevan et al. 2007 
DB[a,l]P:CT 0.8a:400c     - 
 
Abbreviations: B[a]P, benzo[a]pyrene; CSC, cigarette smoke condensate; CT, coal tar; DB[a,l]P, dibenzo[a,l]pyrene; DPE, diesel particulate extract; DPM, diesel particulate matter; UD, urban dust 
 
Symbol guide: a, nmol; b, mg; c, µg; d, mgSRMeq/mlCrudeExtract; +, increase compared to PAH alone; -, decrease compared to PAH alone; =, no observed difference in effect compared to PAH alone 
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